Articles related to CLINICAL STUDY

In a retrospectives study with a 13-month follow up, bariatric surgery patients were 16% less likely to die versus matched non-surgical counterparts. However, surgery patients were more than twice as likely to die by suicide and that risk of suicide was significantly higher in those ages 18-34.

Along with well-known prodromal features like tremor, other signs were identified as potential early indicators. These include sensory skin changes, diabetes, inflammatory conditions, sleep apnea, and restless leg syndrome.

With the initial attempt at salvage therapy, the median PFS was 3.5 months. The objective response rate (ORR) for these patients was 43.4%, with strict complete responses (9.2%), very good partial responses (11.8%), and partial responses (22.4%) all being achieved by patients. A significantly longer median OS of 29.9 months compared to 14.6 months for patients who did not achieve an objective response was associated with achieving a partial response or better with the first line of salvage therapy.

In this cohort study of 12,046 patients with cancer and COVID-19, it was discovered that the use of immunotherapy (IO) and other systemic anticancer therapies in combination with baseline immunosuppression was linked to worse outcomes and a higher incidence of cytokine storm in SARS-CoV-2-infected cancer patients.

This study provides evidence that older patients with Binet stage A CLL, including those in the oldest age groups, can receive the Chronic Lymphocytic Leukemia International Prognostic Index (CLL-IPI). Because of the high median age in our study, we were also able to identify a relationship between del(17p) and age, which raises the possibility that age-adjusted prognostic tools could enhance CLL prediction. In cardiology, risk stratifications and recommendations for antilipid treatment have long taken into account the interaction between age and other risk factors for fatal cardiovascular disease, but in CLL, age is typically only considered as an additive factor in prognostic models.

Aniruddha Hazra, MD, of Howard Brown Health in Chicago, and colleagues found that of 90 people who tested positive for monkeypox following a single dose of Jynneos, 77% of the cases happened within 14 days of the first dose and 14% occurred within 14-28 days of the first dose. Five positive tests were returned following a second dose of the modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine in the eight cases that occurred 28 days after vaccine initiation.